你好,歡迎來到山東省眼科醫院,現在是:
醫院快訊
當前位置:首頁 >> 新聞中心 >> 醫院快訊

EN喜報!史偉云教授獲省科學技術最高獎

日期:2018/04/19 16:17  字號:T|T
山東省人民政府網站顯示,根據《山東省科學技術獎勵辦法》規定,經省科學技術獎勵評審委員會評審、省科學技術獎勵委員會審定和省科技廳審核,2017年度山東省科學技術獎勵出爐,山東省眼科研究所史偉云教授獲得山東省科學技術最高獎,成為兩位最高獎的獲得者之一。
作為全國人大代表,山東省眼科研究所所長、黨委書記,中華醫學會眼科學分會常委、角膜病組組長,山東省泰山學者攀登計劃專家,史偉云教授已從事眼科醫學三十多年。近年來,他先后榮獲中華眼科學會杰出成就獎、吳階平—保羅·楊森醫學藥學獎、美國眼科學會成就獎等重量級獎項,是當下中國大陸眼科學領域最具代表性的專家之一。
據了解,史偉云教授首次提出的睫狀體-虹膜通路,是引起角膜移植排斥另一途徑的創新理論,并據此研發了我國首個具有獨立知識產權的眼內植入緩釋藥物,獲得CFDA藥物臨床試驗批件。
他還創新深板層角膜移植治療圓錐角膜的方法,打破了圓錐角膜只能行穿透性移植的傳統觀點。同時,與導師謝立信院士一起提出“不同真菌在角膜內存在不同生長方式”創新理論,打破了不能應用板層角膜移植治療真菌性角膜炎的傳統觀點,使手術長期成功率超過95%。創造性應用多層羊膜移植治療基質壞死型角膜炎,使這一世界難題取得突破性進展。
目前,史偉云教授已累計為全國30余省市的1萬多名疑難角膜病患者實現復明,成為國內極少獨立完成萬余例疑難角膜移植手術的眼科專家。

史偉云,現任山東省眼科研究所黨委書記、所長,山東省眼科醫院院長,是山東省泰山學者攀登計劃專家、山東省有突出貢獻的中青年專家、山東省首屆醫學領軍人才、第十三屆全國人民代表大會代表、中華醫學會眼科分會第十一屆委員會常務委員、角膜病學組組長,中華眼科學分會專家委員,國務院特殊津貼享受者。
史偉云教授1989年開始跟隨我國著名眼科專家謝立信院士攻讀碩、博士,并獲眼科學博士學位。2000年赴美國,跟隨世界角膜病大師Kaufman教授繼續角膜病的基礎研究工作。2007年被青島大學、2008年被山東大學分別聘為博士生導師。
史偉云教授從事眼科基礎研究及臨床診治工作30余年,是山東大學、青島大學、濟南大學、濰坊醫學院眼科學教授和博士生導師,兼任《中華眼科雜志》副總編輯,《中華眼視光學與視覺科學雜志》、《中國眼耳鼻喉科雜志》、《臨床眼科雜志》、《眼科》編委、山東省眼科學分會副主任委員。
史偉云教授在臨床工作方面,具有豐富的臨床經驗和嫻熟的眼科顯微手術技巧,能熟練完成各類疑難和復雜的眼前段手術。

Congratulations! Prof. Weiyun SHI Won the Highest Science and Technology Award of Shandong Province

?

As reported on the official website of People’s Government of Shandong Province, according to the regulations in Reward Measures for Science and Technology Awards of Shandong Province, after the evaluation by the Evaluation Committee of the Provincial Science and Technology Awards, the approval by the Committee of the Provincial Science and Technology Awards and the review by the Department of Science and Technology of Shandong Province, the Shandong Provincial Science and Technology Awards of 2017 are published. Prof. Weiyun SHI of Shandong Eye Institute won the Highest Science and Technology Award of Shandong Province, becoming one of the two highest prize winners.

Prof. SHI, as a deputy to the National People’s Congress, the director and the secretary of the Party Committee of Shandong Eye Institute, a member of the Standing Committee of the Ophthalmology Society of Chinese Medical Association, the leader of the Corneal Group and an expert of Taishan Scholar Program of Shandong Province, has been engaged in ophthalmology for more than 30 years. In recent years, he has received many important awards such as the Outstanding Achievement Award of Chinese Ophthalmology Society, Wu Jieping Medical Research Award–Paul Janssen Pharmaceutical Research Award, the Achievement Award of American Academy of Ophthalmology. Professor SHI is one of the most representative experts in ophthalmology in mainland China.

The iris-ciliary body pathway, first proposed by Prof. SHI, is an innovative theory for corneal graft rejection. Based on this research achievement, he developed the first ocular implantable sustained-release drug with independent intellectual property in China and gained the clinical trial permission for drugs from CFDA.

Prof. SHI also made innovations in deep lamellar keratoplasty to treat keratoconus, breaking the traditional view that keratoconus can only be treated by penetrating keratoplasty. Prof. SHI also proposed an innovative theory that “different fungi have different growth patterns in the cornea” with Academician Lixin XIE, who is his supervisor, breaking the traditional view that lamellar keratoplasty cannot be used to treat fungal keratitis and achieving a long-term surgery success rate of more than 95%. The creative application of multilayer amniotic membrane transplantation by Prof. SHI is a breakthrough to the worldwide problem of treating necrotizing stromal keratitis.

Up to now, Prof. SHI has helped more than 10,000 patients with difficult corneal diseases from more than 30 provinces and cities nationwide to regain sight. Prof. SHI is one of the few ophthalmologists in China that have performed more than 10,000 difficult corneal transplantation surgeries independently.

?

人人操逼网